Skip to main content
NewslettersWatchlist

Compugen Ltd(CGEN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.11
Day High2.29
Open:2.17
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
5 Growth Stocks Under $10 to Scoop Up Now
AllPennyStocks.com
Strong Open For Biotech Following Exclusive Agreement Announcement
PR Newswire
Compugen to Present at Single Cell Genomics 2023 Meeting
PR Newswire
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
PR Newswire
Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference
PR Newswire
Compugen Reports Second Quarter 2023 Results
PR Newswire
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023
PR Newswire
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party
PR Newswire
Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study
PR Newswire
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
PR Newswire
Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer
PR Newswire
Compugen Reports First Quarter 2023 Results
PR Newswire
Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023
PR Newswire
Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023
PR Newswire
Compugen to Present New Clinical Data Showing Preliminary Anti-Tumor Activity of COM701 Triple Combination in Recurrent MSS-Metastatic Endometrial Cancer at ASCO 2023
PR Newswire
Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting
PR Newswire
Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
Motley Fool
Why Compugen Shares Are Up Today
PR Newswire
Compugen Reports Fourth Quarter and Full Year 2022 Results
PR Newswire
Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3
PR Newswire
Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023
PR Newswire
Compugen to Present at the SVB Securities Global Biopharma Conference
Motley Fool
Why Compugen Stock Got Slammed Today
PR Newswire
Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview
Motley Fool
Why Shares of Compugen Rose on Thursday
PR Newswire
Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients
Motley Fool
Why Shares of Compugen Rose 16.5% on Wednesday
PR Newswire
Compugen to Participate in the JMP Securities Hematology and Oncology Summit
Motley Fool
Why Shares of Compugen Jumped 17.86% on Thursday
Motley Fool
Why Compugen Stock Crumbled Today
PR Newswire
Compugen Reports Third Quarter 2022 Results
PR Newswire
Compugen to Participate in the Stifel Healthcare Conference

Profile

Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.